Decision Analysis: Omadacycline Relative to Moxifloxacin Among Hospitalized Community-Acquired Bacterial Pneumonia Patients at Risk of Clostridioides difficile Infection
Open Access
- 19 February 2021
- journal article
- research article
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 41 (3) , 269-275
Abstract
Background and Objective Omadacycline is an aminomethylcycline antibiotic approved in the USA as once-daily intravenous/oral monotherapy for adults with community-acquired bacterial pneumonia (CABP). Omadacycline demonstrated noninferiority to the fluoroquinolone moxifloxacin in a phase III CABP trial; adverse-event rates were similar between treatment groups except for Clostridioides difficile infection (CDI), which occurred in 2% of moxifloxacin-treated patients and 0% of patients on omadacycline. Conceptual healthcare-decision analytic models were developed to better understand the economic implications of antibiotic selection and CDI risk in acute-care facilities. Methods A conceptual healthcare-decision analytic model was created to estimate incremental costs associated with treating 100 hospitalized CABP patients with an initial 5-day inpatient regimen of omadacycline instead of moxifloxacin. The underlying model assumption was that treatment with omadacycline has the potential to reduce CDI events relative to moxifloxacin. The model included excess costs associated with each treatment group from admission through discharge. Attributable CDI cost per case in the moxifloxacin group varied from $15,000 to $45,000 (US$). Omadacycline acquisition cost was $300–600/day for 5 days. Results At a CDI attributable cost per case of $30,000 (base-case analyses), the incremental treatment cost (US$) per 100 patients ranged from $300,000 to $− 120,000 (cost savings). The excess CDI incidence in moxifloxacin-treated patients would need to be 5–10% for omadacycline to be cost-saving, assuming the attributable CDI cost is approximately $30,000. Conclusion Targeted omadacycline use may reduce economic burden associated with hospitalized CABP patients treated with moxifloxacin if it can reduce excess cases of moxifloxacin-associated CDI.Keywords
Funding Information
- Paratek Pharmaceuticals, Inc.
This publication has 24 references indexed in Scilit:
- Effects of control interventions on Clostridium difficile infection in England: an observational studyThe Lancet Infectious Diseases, 2017
- Cost of hospital management of Clostridium difficile infection in United States—a meta-analysis and modelling studyBMC Infectious Diseases, 2016
- Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic SocietyClinical Infectious Diseases, 2016
- Risk factors for Clostridium difficile infection in hospitalized patients with community-acquired pneumoniaJournal of Infection, 2016
- Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of AmericaClinical Infectious Diseases, 2016
- C. difficile Infection: Changing Epidemiology and Management ParadigmsClinical and Translational Gastroenterology, 2015
- The Economic Impact of Clostridium difficile Infection: A Systematic ReviewAmerican Journal of Gastroenterology, 2015
- Burden ofClostridium difficileInfection in the United StatesNew England Journal of Medicine, 2015
- Community-associated Clostridium difficile infection and antibiotics: a meta-analysisJournal of Antimicrobial Chemotherapy, 2013
- Diagnosis and Management of Complicated Intra-abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2010